BioSpace News Archive

Global biotechnology leader CSL celebrated the official opening of the company’s new state-of-the-art research and development center in Waltham, Massachusetts.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as Executive Vice President, Chief Operating Officer

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT) today announced Douglas J. Swirsky has been appointed as the Company’s Chief Financial Officer, effective immediately.

Applied Molecular Transport Inc. announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

Acer Therapeutics Inc. (Nasdaq: ACER) today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company’s recent corporate developments.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors.

Harpoon Therapeutics, Inc. announced that it has closed a private placement of redeemable preferred stock and warrants to purchase common stock to certain institutional and other accredited investors for aggregate gross proceeds to the Company of $25 million, before deducting offering expenses, which does not include any proceeds that may be received upon exercise of the warrants.

Exicure, Inc. reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced financial results for the fourth quarter and full year ended December 31, 2022.

IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors of the Company, effective immediately.